Efficacy and Safety of Ertugliflozin in Patients with Type 2 Diabetes Inadequately Controlled by Metformin and Sulfonylurea: A Sub-Study of VERTIS CV

INTRODUCTION: VERTIS CV is the cardiovascular outcome trial for the sodium–glucose cotransporter 2 (SGLT2) inhibitor ertugliflozin. A sub-study was conducted to assess the efficacy and safety of ertugliflozin in patients with type 2 diabetes mellitus (T2DM) inadequately glycemic-controlled on metfor...

Descripción completa

Detalles Bibliográficos
Autores principales: Budoff, Matthew J., Davis, Timothy M. E., Palmer, Alexandra G., Frederich, Robert, Lawrence, David E., Liu, Jie, Gantz, Ira, Derosa, Giuseppe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8099972/
https://www.ncbi.nlm.nih.gov/pubmed/33721213
http://dx.doi.org/10.1007/s13300-021-01033-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8099972/
https://www.ncbi.nlm.nih.gov/pubmed/33721213
http://dx.doi.org/10.1007/s13300-021-01033-x

Ejemplares similares